Japan To Lower Price Caps On Key Prescription Drugs
This article was originally published in PharmAsia News
Japan plans new price caps on prescription drugs in April, lowered by an average of 5.2 percent. Some of the most popular drugs produced by major drug makers face an even steeper reduction in the maximum price allowed, by 10.1 percent. The new caps are expected to cause more pharmaceutical makers to shift their focus from marketing drugs in Japan to other countries. Among drugs facing the greatest price reduction are those in a new generation of medicines to lower blood pressure, including Takeda's Blopress (candesartan cilexetil), Astellas' Micardis (telmisartan) and Daiichi Sankyo's Olmetec (olmesartan). (Click here for more - a subscription may be required
You may also be interested in...
Avadim Health argues National Advertising Division expects substantiation for its homeopathic topical claims at the same level FDA requires for NDAs. NAD also said although FTC’s competent, reliable scientific evidence standard is “flexible” to some degree, pain claims are held to a more rigid standard.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
The FDA has asked the company for more information to support its PoNS therapy for multiple sclerosis patients with gait deficit, including an additional analysis of clinical data and labeling modifications.